JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024. "We continue to deliver strong execution with key milestones achieved during the second quarter of 2024 across each of our N-Tab™ oral peptide programs dedicated to patients with OBGYN/endocrinology, GI and metabolic disea ...

JERUSALEM, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that new comparative pharmacological data for its investigational agent EB613 vs. Forteo® was selected for presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting which will be held on September 27-30, 2024 in Toronto, ON, Canada. EB613 is being developed as the first o ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Entera Bio Ltd. (ENTX) been one of those stocks this year? A quick glance at the company's yearto-date performance in comparison to the rest of the Medical sector should help us answer this question. Entera Bio Ltd. is one of 1046 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuri ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Entera Bio Ltd. (ENTX) been one of those stocks this year? A quick glance at the company's yearto-date performance in comparison to the rest of the Medical sector should help us answer this question. Entera Bio Ltd. is one of 1048 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, m ...

JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that it has been selected to present data for its investigational program EB612 at the Endocrine Society ENDO 2024 Annual Meeting which will be held on June 1-4, 2024 in Boston, Massachusetts. The EB612 program is being developed by Entera to provide the first oral PTH(1-34) tablet peptide replacement t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38556 ENTERA BIO LTD. (Exact name of Registrant as specified in its charter) Israel Not applicable (State or other jurisdiction of (I.R.S. ...

Exhibit 99.1 Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates JERUSALEM – May 10th, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024. “Entera is off to a strong start in 2024 thanks to the growth strategy we implemented in 2023, expanding our N-Tab™ therapeutic pipe ...

JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended March 31, 2024. "Entera is off to a strong start in 2024 thanks to the growth strategy we implemented in 2023, expanding our N-Tab™ therapeutic pipeline with potential first in class oral GLP-2, GLP-1/glucagon and PTH(1-34) peptide treatmen ...

Entera Bio Ltd. (ENTX) closed at $1.98 in the latest trading session, marking a -1% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 1.02%. Meanwhile, the Dow gained 0.4%, and the Nasdaq, a tech-heavy index, added 2.03%.Shares of the company witnessed a gain of 19.76% over the previous month, beating the performance of the Medical sector with its loss of 5.2% and the S&P 500's loss of 3.15%.The investment community will be paying close attention to the earnings perform ...

公司股价表现 - Entera Bio Ltd. (ENTX) 最近的交易日收盘价为$2.24，较前一日收盘价上涨了+0.9% [1] - 公司股价表现优于标普500指数的日损失0.22% [1] - 过去一个月，公司股价上涨了46.05%，超过医疗行业的损失6.22%和标普500指数的损失1.66% [3] 财务预测 - 公司预计在即将发布的财报中将发布每股收益为-$0.06，较去年同期增长25% [4] 分析师评级 - 最近分析师对Entera Bio Ltd.的估值发生了变化，这些变化通常反映了最新的短期业务趋势 [5] - 根据研究，估值变化与近期股价走势直接相关，公司目前持有Zacks Rank 1（强烈买入） [6] 行业评级 - 医疗-生物医学和遗传学行业属于医疗行业，目前Zacks行业排名为82，位于所有行业的前33% [8] - Zacks行业排名评估了我们各个行业群体的实力，研究显示排名前50%的行业的表现是排名后50%的两倍 [9] 未来展望 - 在未来的交易中，请使用Zacks.com跟踪这些股票动态指标 [10]